Safety, Efficacy, and Drug Survival of Colchicine in Recurrent Aphthous Stomatitis in a Real-World Setting
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Recurrent aphthous stomatitis (RAS) is a common disorder characterized by episodic ulcerations in the oral mucosa. Although colchicine has been a common systemic treatment for RAS, there is still considerable uncertainty regarding its efficacy and drug survival in this setting. Objective: We aimed to study drug survival, efficacy, and safety of colchicine for the treat- ment of RAS, especially in the real clinical setting. Methods: Between 2012 and 2016, 150 patients given colchicine for RAS were selected for a single-centre retrospective study of real-world efficacy and drug survival. Results: Among the 114 patients who qualified, 81.6% showed moderate or substantial re- sponses (>25% improvement). Gastrointestinal complications (16.7%), neutropenia (3.5%), and liver enzyme elevation (4.4%) were reported within 2 weeks after initiating treatment. Delayed adverse manifestations were rare. One year after onset, colchicine use was sus- tained in roughly one-half (49.5%) of patients, whereas many (30.3%) had discontinued the drug, primarily due to lack of efficacy or adverse events. In Cox proportional hazard analysis, minor ulcers were identified as potential determinants of longer drug survival owing to less probability of non-efficacy. However, major ulcers had emerged as predictors of early discontinuation due to lack of efficacy. Conclusion: In patients with RAS, colchicine may be an effective and safe treatment ame- nable to long-term maintenance. Monitoring of adverse events within 2 weeks after initi- ating treatment is advisable to ensure safe administration.
Abstract
Background: Recurrent aphthous stomatitis (RAS) is a common disorder characterized by episodic ulcerations in the oral mucosa. Although colchicine has been a common systemic treatment for RAS, there is still considerable uncertainty regarding its efficacy and drug survival in this setting. Objective: We aimed to study drug survival, efficacy, and safety of colchicine for the treat- ment of RAS, especially in the real clinical setting. Methods: Between 2012 and 2016, 150 patients given colchicine for RAS were selected for a single-centre retrospective study of real-world efficacy and drug survival. Results: Among the 114 patients who qualified, 81.6% showed moderate or substantial re- sponses (>25% improvement). Gastrointestinal complications (16.7%), neutropenia (3.5%), and liver enzyme elevation (4.4%) were reported within 2 weeks after initiating treatment. Delayed adverse manifestations were rare. One year after onset, colchicine use was sus- tained in roughly one-half (49.5%) of patients, whereas many (30.3%) had discontinued the drug, primarily due to lack of efficacy or adverse events. In Cox proportional hazard analysis, minor ulcers were identified as potential determinants of longer drug survival owing to less probability of non-efficacy. However, major ulcers had emerged as predictors of early discontinuation due to lack of efficacy. Conclusion: In patients with RAS, colchicine may be an effective and safe treatment ame- nable to long-term maintenance. Monitoring of adverse events within 2 weeks after initi- ating treatment is advisable to ensure safe administration.
참고문헌 (20)
- Cui RZ, "Recurrent aphthous stomatitis", Clin Dermatol, 34, pp.475~481 (2016)
- Ship JA, "Recurrent aphthous stomatitis. An update", Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 81, pp.141~147 (1996)
- Chattopadhyay A, "Risk indicators for recurrent aphthous ulcers among adults in the US", Community Dent Oral Epidemiol, 35, pp.152~159 (2007)
- Leung YY, "Colchicine--Update on mechanisms of action and therapeutic uses", Semin Arthritis Rheum, 45, pp.341~350 (2015)
- Slobodnick A, "Colchicine : old and new", Am J Med, 128, pp.461~470 (2015)
- Pakfetrat A, "Comparison of colchicine versus prednisolone in recurrent aphthous stomatitis : a doubleblind randomized clinical trial", Clin Invest Med, 33, pp.189~195 (2010)
- Mizushima Y, "Revised diagnostic criteria for Behçet’s disease in 1987", Ryumachi, 28, pp.66~70 (1988)
- Edgar NR, "Recurrent aphthous stomatitis : a review", J Clin Aesthet Dermatol, 10, pp.26~36 (2017)
- Bagán JV, "Recurrent aphthous stomatitis. A study of the clinical characteristics of lesions in 93 cases", J Oral Pathol Med, 20, pp.395~397 (1991)
- Oh SH, "Comparison of the clinical features of recurrent aphthous stomatitis and Behçet’s disease", Clin Exp Dermatol, 34, pp.e208~ (2009)
- Katz J, "Prevention of recurrent aphthous stomatitis with colchicine : an open trial", J Am Acad Dermatol, 31(3 Pt 1), pp.459~461 (1994)
- Fontes V, "Recurrent aphthous stomatitis : treatment with colchicine. An open trial of 54 cases", Ann Dermatol Venereol, 129, pp.1365~1369 (2002)
- Lynde CB, "Successful treatment of complex aphthosis with colchicine and dapsone", Arch Dermatol, 145, pp.273~276 (2009)
- Saad AA, "Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis : observational study from the British Society of Rheumatology Biologics Register", Arthritis Res Ther, 11, pp.R52~ (2009)
- Krause I, "Recurrent aphthous stomatitis in Behçet’s disease : clinical features and correlation with systemic disease expression and severity", J Oral Pathol Med, 28, pp.193~196 (1999)
- Sun A, "Levamisole and Chinese medicinal herbs can modulate the serum interleukin-6 level in patients with recurrent aphthous ulcerations", J Oral Pathol Med, 32, pp.206~214 (2003)
- Sun A, "Serum interleukin-8 level is a more sensitive marker than serum interleukin-6 level in monitoring the disease activity of recurrent aphthous ulcerations", J Oral Pathol Med, 33, pp.133~139 (2004)
- Davatchi F, "Colchicine versus placebo in Behçet’s disease : randomized, double-blind, controlled crossover trial", Mod Rheumatol, 19, pp.542~549 (2009)
- Yurdakul S, "A double-blind trial of colchicine in Behçet’s syndrome", Arthritis Rheum, 44, pp.2686~2692 (2001)
- Chang HK, "HLA-B51 and its allelic types in association with Behçet’s disease and recurrent aphthous stomatitis in Korea", Clin Exp Rheumatol, 19(5), pp.S31~S35 (2001)